Results 31 to 40 of about 278,336 (309)

Preoperative CYFRA 21-1 and CEA as Prognostic Factors in Patients with Stage I Non-Small Cell Lung Cancer [PDF]

, 2008
Objective: To validate the prognostic value of preoperative levels of CYFRA 21-1, CEA and the corresponding tumor marker index (TMI) in patients with stage I non-small cell lung cancer (NSCLC). Methods: Two hundred forty stage I NSCLC patients (80 in pT1
Hatz, Rudolf, Gruber, Christine, Reinmiedl, Judith, Ankerst, Donna Pauler, Seidel, Dietrich, Blankenburg, Florian, Stieber, Petra, Nagel, Dorothea, Blankenburg, F.;Hatz, R.;Nagel, D.;Ankerst, D.;Reinmiedl, J.;Gruber, C.;Seidel, D.;Stieber, P.   +8 more
core   +1 more source

Új lehetőségek az NSCLC szisztémás kezelésében

, 2023
Az irodalmi összefoglaló dolgozatom témája a nem kissejtes tüdőrák esetében vizsgálható prediktív biomarkerek, és ezáltal elérhető célzott terápiás kezelés.
Balog, Ádám
core  

The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancer

Исследования и практика в медицине, 2021
Currently, lung cancer is a global problem and public health issue in the world. Chemoradiotherapy remains the optimal method in the treatment of patients with unresectable non-small cell lung cancer (NSCLC).
E. I. Smolenov, G. V. Afonin, V. S. Usachev, D. D. Kudryavtsev, I. V. Kolobaev, S. A. Ivanov   +5 more
doaj   +1 more source

Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics. [PDF]

, 2022
Continuous revision of the histologic and stage-wise classification of lung cancer by the World Health Organization (WHO) provides the foundation for therapeutic advances by promoting molecular targeted and immunotherapies and ensuring accurate diagnosis.
Gopalakrishnan, Abilash Valsala, Dey, Abhijit, Wilson, Cornelia M, George, Alex, Rajanikant, Golgodu Krishnamurthy, Wanjari, Uddesh Ramesh, Al-Yozbaki, Minnatallah, Dewanjee, Saikat, John, Mithun Chacko, Renu, Kaviyarasi, Mukherjee, Anirban Goutam, Padinharayil, Hafiza, Sanyal, Rupa, Varghese, Jinsu   +13 more
core   +1 more source

Molecular docking study of sea urchin (Arbacia lixula) peptides as multi-target inhibitor for non-small cell lung cancer (NSCLC) associated proteins

, 2021
Context: Lung cancer is a type of cancer that causes the most deaths worldwide. The most common type of lung cancer is non-small cell lung cancer (NSCLC). Sea urchin (Arbacia lixula) has high potential as an antiNSCLC agent.
Ansori, Arif Nur Muhammad, Sari, Fikriya Novita, Kharisma, Viol Dhea, Samoedra, Rizky Senna, Antonius, Yulanda, Widyananda, Muhammad Hermawan, Pratama, Setyaki Kevin   +6 more
core   +2 more sources

Pattern of care in locally advanced non-small cell lung cancer: A tertiary care experience from India

Lung India
Introduction and Objective: Heterogeneity in locally advanced (LA) Non-Small Cell Lung Cancer (NSCLC) group necessitates a multi-disciplinary approach to its management. Surgery is the standard of care treatment if resectable; otherwise, concurrent chemo-
Aswin Ravi, Sushmita Pathy, Supriya Mallick, Prabhat S. Malik, Sunil Kumar, Rajeev Kumar   +5 more
doaj   +1 more source

Long Noncoding RNA LINC01426 Sequesters microRNA-519d-5p to Promote Non-Small Cell Lung Cancer Progression by Increasing ETS1 Expression [Retraction]

Cancer Management and Research, 2023
Dai J, Wang B, Zhao Y, et al. Cancer Manag Res. 2020;12:12697–12708. At the authors request, the Editor and Publisher of Cancer Management and Research wish to retract the published article.
Dai J, Wang B, Zhao Y, Zuo X, Cui H, Chen X, Liu X   +6 more
doaj  

Role of Serum Tumor Markers in Prognosis of Operable Non-small Cell Lung Cancer Patients

Zhongliu Fangzhi Yanjiu, 2018
Objective To evaluate the prognostic value of CEA, CA125, CA199, NSE, CYFRA21-1 and SCC-Ag as serum tumor markers on the diagnosis of operable non-small cell lung cancer(NSCLC) after radical operation.
LI Shaolei, MA Yuanyuan, XIONG Ying, ZHANG Shanyuan, HUANG Miao, YANG Yue   +5 more
doaj   +1 more source

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC

Pharmaceutics, 2020
c-Met is a receptor tyrosine kinase with no commercially available product despite being a pivotal target in cancer progression. Unlike other c-Met inhibitors that fail clinically, ABN401 is a newly synthesized c-Met inhibitor that is not potentially ...
Nam Ah Kim, Sungyoul Hong, Ki Hyun Kim, Du Hyung Choi, Joo Seok Kim, Kyung Eui Park, Jun Young Choi, Young Kee Shin, Seong Hoon Jeong   +8 more
doaj   +1 more source

Pharmacoepidemiology analysis of high cost drugs used in the treatment of NSCLC in the upper Padua (Ulss 6 Euganea)

, 2023
reservedLo studio ha lo scopo di analizzare l’outcome delle terapie per il carcinoma del polmone non a piccole cellule nella real-life negli ospedali della Regione del Veneto di Camposampiero e Cittadella (Ulss Euganea n. 6).
LAZZARO, ROSSELLA
core